Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 19/20 | 0.78 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5807893 | 0.93 | CASR (0.75) | CASRTDO2IDO2 | |
| SCHEMBL5813807 | 0.88 | CASR (0.74) | CASRTDO2IDO2 | |
| SCHEMBL5747533 | 0.88 | CASR (1.00) | CASR | |
| SCHEMBL5749267 | 0.86 | CASR (0.88) | CASR | |
| SCHEMBL5745364 | 0.85 | CASR (0.79) | CASRTDO2IDO2 | |
| SCHEMBL5750312 | 0.85 | CASR (1.00) | CASR | |
| SCHEMBL27616917 | 0.84 | CASR (0.77) | CASRTDO2IDO2 | |
| SCHEMBL5781863 | 0.83 | CASR (0.70) | CASRTDO2IDO2 | |
| SCHEMBL5750691 | 0.83 | CASR (0.66) | CASRTDO2IDO2 | |
| SCHEMBL5750250 | 0.83 | CASR (0.66) | CASRTDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558260-A4 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | NPS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1558260-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041755-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | CALCR, CALCRL, CASR | CASR 3/4885TDO2 3738/4885IDO2 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.